Trial reportDiabetes, obesity & metabolism2012
Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.
Trial report in Diabetes, obesity & metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Journal of endocrinological investigation · 2016Guideline
- Effects of combined metformin and cabergoline versus metformin alone on ovarian and hormonal activities in Iraqi patients with PCOS and hyperprolactinemia: a randomized clinical trial.Journal of medicine and life · 2023Trial
- Pharmaceutical interventions for weight-loss maintenance: no effect from cabergoline.International journal of obesity (2005) · 2018Trial
- Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.Medicine · 2016Trial
- Effect of cabergoline on the management of diabetes mellitus: a systematic review and meta-analysis.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly.Journal of endocrinological investigation · 2024Article
- Metabolic and inflammatory parameters in relation to baseline characterization and treatment outcome in patients with prolactinoma: insights from a retrospective cohort study at a single tertiary center.Frontiers in endocrinology · 2024Article
- Growth hormone receptor in dopaminergic neurones regulates stress-induced prolactin release in male mice.Journal of neuroendocrinology · 2021Article
- Central dopamine DScientific reports · 2020Article
- The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'.European endocrinology · 2020Review
- Dopaminergic Pathways in Obesity-Associated Inflammation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.Internal medicine (Tokyo, Japan) · 2019Article
- Review
- Hypothalamic dopamine signaling regulates brown fat thermogenesis.Nature metabolism · 2019Article
- Deep Brain Stimulation for Obesity: A Review and Future Directions.Frontiers in neuroscience · 2019Review
- Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.Endocrine connections · 2018Review
- Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment.Frontiers in endocrinology · 2018Review
- Does Twice-weekly Cabergoline Improve Anthropometrical and Biochemical Profiles in Prediabetes? A Randomized Double-blind Clinical Trial Pilot Study.Iranian journal of pharmaceutical research : IJPR · 2015Article
- Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline.Diabetology & metabolic syndrome · 2015Article
- The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.Pituitary · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
aimDopaminergic hypofunction and hyperprolactinaemia have been implicated in the pathogenesis of obesity and glucose intolerance. The aim of this pilot study was to determine the efficacy of cabergoline, a dopamine receptor agonist, on body weight and glucose tolerance in obese non-diabetic persons with normal plasma prolactin levels.
methodsThis 16-week double blind, placebo-controlled pilot study randomized non-diabetic obese adults (body mass index 30-42 kg/m(2) ) to placebo or cabergoline (0.25 mg twice weekly for 4 weeks followed by 0.5 mg twice weekly for the next 12 weeks). Of 40 subjects enrolled, 29 completed 16 weeks: 16 randomized to placebo and 13 to cabergoline. All subjects were counselled on a 500 kcal/day calorie deficit diet. A 75-g oral glucose tolerance test was performed at baseline and at 16 weeks.
resultsAs expected, prolactin levels decreased after cabergoline (p < 0.001). Weight loss was similar after placebo compared with cabergoline treatment: 1.0 vs. 1.2% body weight, respectively. Fasting glucose levels did not differ between groups after treatment, however, 90-min postprandial glucose and insulin decreased in the cabergoline group only (p = 0.029). HOMA-IR (homeostasis model of assessment) increased by 40% after placebo and 1.5% after cabergoline treatment.
conclusionsThis pilot study suggests that cabergoline therapy may improve glucose tolerance independent of weight loss, however, a larger, longer term study of dopamine receptor agonist therapy in obese individuals is warranted to confirm this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.